Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07370532

Etoricoxib in Patients With Parkinsonian Disease

Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

50 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Mansoura University

Al Mansurah, 26548, Egypt

Location status: Recruiting

Location contact

Ehab Hassan, PhD

CONTACT

[email protected]

01067831661

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Both male and female will be included.
  • Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

Exclusion criteria

  • Breast feeding
  • Patients with significant liver and kidney function abnormalities.
  • Alcohol and / or drug abusers.
  • Patients with known allergy to the study medications
  • Pregnant women and women with planned pregnancy.
  • Patients who are currently using other anti-inflammatory drugs.

Treatment and study plan

L-DOPA

Drug

Levodopa is the standard therapy in PD.

Etoricoxib

Drug

Etoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia.

Primary outcomes

  1. - Change in The Unified Parkinson's Disease Rating Scale

    Time frame: 6 months

    • Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score

Sponsors and collaborators

Lead sponsor

Ihab Elsayed Hassan

Other

Registry information

Official study title

Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 27, 2026
Registry last updated
Apr 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.